임상시험용 인공지능(AI) 시장 : 전략적 인사이트와 예측(2026-2031년)

The Global Artificial Intelligence (AI) in Clinical Trials market is forecast to grow at a CAGR of 43.92%, reaching USD 46.9 billion in 2031 from USD 7.6 billion in 2026.

The artificial intelligence in clinical trials market is emerging as a critical component of modern drug development and clinical research optimization. Pharmaceutical companies, biotechnology firms, and research organizations are increasingly adopting AI technologies to address inefficiencies in traditional clinical trial processes. Clinical trials have historically been resource intensive, time consuming, and subject to high failure rates. Artificial intelligence offers advanced data analytics, predictive modeling, and automation capabilities that enhance trial design, patient recruitment, and monitoring processes.

The market is being shaped by growing global demand for faster drug development, particularly for rare and genetic diseases. Increasing healthcare data availability and the need for precision medicine are accelerating adoption of AI driven clinical research tools. AI technologies enable pharmaceutical companies to analyze large datasets, improve trial population diversity, and enhance decision making throughout the trial lifecycle. As research pipelines become more complex and cost pressures intensify, AI solutions are gaining strategic importance in improving efficiency, reducing operational risks, and increasing success probabilities in clinical trials.

Market Drivers

One of the key growth drivers is the rising need for efficient drug discovery and development. Pharmaceutical firms are leveraging AI to streamline trial planning, reduce costs, and accelerate time to market. AI enables faster data processing, predictive analytics, and real time monitoring, which help improve trial outcomes and reduce operational complexity.

Growing research into rare and genetic diseases is also driving demand. AI supports the identification of suitable patient populations, improves biomarker analysis, and enhances protocol optimization. These capabilities are particularly valuable in complex therapeutic areas where conventional methods may be inefficient.

Another important driver is increasing adoption by pharmaceutical companies and research organizations. Major drug manufacturers are collaborating with AI technology providers or developing in house capabilities to enhance clinical trial design and execution. The expanding number of clinical trials globally further supports market growth by creating demand for scalable analytical tools.

Market Restraints

Despite strong growth prospects, the market faces several operational and structural challenges. Integration of AI into clinical research requires advanced data infrastructure, skilled personnel, and regulatory compliance frameworks. These requirements can increase implementation complexity and cost.

Data quality and standardization also present challenges. Clinical trial data originates from multiple sources, including electronic health records, wearable devices, and monitoring systems. Ensuring interoperability and accuracy across datasets can be difficult and may limit AI performance in certain applications.

Regulatory and ethical considerations further constrain adoption. Clinical research requires strict compliance with safety and privacy standards, which can slow deployment of new technologies and increase approval timelines.

Technology and Segment Insights

The market spans several process based applications, including trial design, patient selection, site selection, and patient monitoring. AI tools are integrated across the full clinical development lifecycle, from protocol development to post trial analysis.

Application segments include biosensors, smartphone applications, and wearable technologies. These solutions enable real time data collection, remote monitoring, and continuous patient engagement. Such capabilities support decentralized and hybrid clinical trial models, improving data quality and patient participation.

AI technologies are increasingly used to automate data analysis, enhance recruitment strategies, and improve outcome prediction. Machine learning algorithms support pattern recognition and predictive modeling, enabling researchers to identify risks earlier and optimize study design.

Regionally, North America holds a significant share due to high healthcare expenditure, advanced research infrastructure, and strong adoption of digital health technologies.

Competitive and Strategic Outlook

The competitive landscape includes specialized AI clinical research firms and technology providers offering analytics platforms, data management solutions, and trial optimization tools. Strategic partnerships between pharmaceutical companies and AI developers are a defining feature of the market.

Companies are focusing on expanding AI capabilities across clinical development workflows, including predictive trial design, automated monitoring, and digital patient engagement. Investment in research and innovation remains strong as organizations seek to improve trial efficiency and reduce development risk.

Key Takeaways

Artificial intelligence is reshaping clinical trial operations by improving efficiency, reducing costs, and enhancing data driven decision making. As pharmaceutical innovation accelerates and trial complexity increases, AI adoption is expected to expand significantly. While regulatory and data integration challenges remain, the long term outlook for AI enabled clinical research remains highly positive.

Key Benefits of this Report

• Insightful Analysis: Gain detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What businesses use our reports for

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2025 and forecast data from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

• 2.1. Research Data
• 2.2. Research Design

3. EXECUTIVE SUMMARY

• 3.1. Research Highlights

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. AI IN CLINICAL TRIALS MARKET BY PROCESS

• 5.1. Introduction
• 5.2. Trial Design
• 5.3. Patient Selection
• 5.4. Site Selection
• 5.5. Patient Monitoring

6. AI IN CLINICAL TRIALS MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Biosensors
• 6.3. Smartphone Applications
• 6.4. Wearables

7. AI IN CLINICAL TRIALS MARKET BY GEOGRAPHY

• 7.1. Introduction
• 7.2. North America
  • 7.2.1. USA
  • 7.2.2. Canada
  • 7.2.3. Mexico
• 7.3. South America
  • 7.3.1. Brazil
  • 7.3.2. Argentina
  • 7.3.3. Others
• 7.4. Europe
  • 7.4.1. United Kingdom
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Others
• 7.5. Middle East and Africa
  • 7.5.1. Saudi Arabia
  • 7.5.2. UAE
  • 7.5.3. Others
• 7.6. Asia Pacific
  • 7.6.1. China
  • 7.6.2. Japan
  • 7.6.3. India
  • 7.6.4. South Korea
  • 7.6.5. Australia
  • 7.6.6. Indonesia
  • 7.6.7. Vietnam
  • 7.6.8. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 8.1. Major Players and Strategy Analysis
• 8.2. Emerging Players and Market Lucrativeness
• 8.3. Mergers, Acquisitions, Agreements, and Collaborations
• 8.4. Market Share Analysis

9. COMPANY PROFILES

• 9.1. ConcertAI
• 9.2. Saama Technologies LLC
• 9.3. PathAI
• 9.4. Owkin Inc.
• 9.5. Aitia
• 9.6. Neuroute
• 9.7. AiCure
• 9.8. Unlearn AI
• 9.9. VeriSIM Life